PEVONEDISTAT (TAK-924): A POTENTIAL NEW TREATMENT FOR HR-MDS AND AML
Phil Rowlands, PhD
Head Oncology Therapeutic Area Unit Takeda Pharmaceutical Company Limited New York, NY November 14, 2019
BUILDING ON THE TAKEDA ONCOLOGY FOUNDATION IN HEMATOLOGIC MALIGNANCIES
Next Generation I/O
Cell therapies Type I IFN Novel checkpoints
GROWING LEADERSHIP POSITION IN HEMATOLOGIC MALIGNANCIES
Lymphoma
MDS/AML Phase 3 pevonedistat
Chronic Myeloid Leukemia
Improving Patient Outcomes in Multiple Myeloma
79
HIGH RISK MYELODYSPLASTIC SYNDROME (HR-MDS) AND ACUTE MYELOID LEUKEMIA (AML) HAVE LIMITED TREAT